EU Regulator Warns of Prolonged Shortage for Baxter's Key Cancer Drug Until Early 2027
BAX is trading near its 52-week low of $16.08 (2.1% above the low).
Summary
The European Union's medicines regulator has issued a warning that Baxter International's cancer treatment containing ifosfamide will face a prolonged shortage across the bloc until early 2027. This significant disruption stems from a technical issue at a contract manufacturing site, impacting a critical product for which Baxter is the primary EU supplier. This development adds to a challenging period for Baxter, which recently reported a net loss, substantial impairments, and product recalls in its last 10-K, and follows a prior warning regarding a shortage of another cancer drug, cyclophosphamide. The extended unavailability of a key pharmaceutical product is expected to negatively impact the company's revenue, market share, and reputation, further pressuring a stock already trading near its 52-week low. Traders will be closely monitoring updates on manufacturing resolution and any potential revisions to financial guidance.
At the time of this announcement, BAX was trading at $16.41 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.4B. The 52-week trading range was $16.08 to $34.52. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.